- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD); severe asthma
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 871KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 47KB)
Tiotropium – July 2020
Tiotropium: Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations); Sprivia® Respimat®
Last updated
30 October 2020